Exelixis, Inc. (EXEL)

業務介紹

Exelixis, Inc.是一家專注於腫瘤學的生物科技公司，致力於在美國發現、開發和商業化新藥物以治療癌症。該公司的產品包括CABOMETYX片劑，用於治療先前接受抗血管生成治療的晚期腎細胞癌患者；以及COMETRIQ膠囊，用於治療進展性轉移性髓樣甲狀腺癌患者。其CABOMETYX和COMETRIQ均源於cabozantinib，一種抑制多種酪氨酸激酶（包括MET、AXL、RET和VEGF受體）的藥物。該公司還提供COTELLIC，一種MEK抑制劑，作為組合療法用於治療晚期黑色素瘤；以及MINNEBRO，一種口服非類固醇選擇性礦物質皮質激素受體阻滯劑，用於日本高血壓的治療。此外，該公司還正在開發XL092，一種口服酪氨酸激酶抑制劑，靶向VEGF受體、MET、AXL、MER和其他與癌症生長和擴散有關的激酶；XB002，一種由人源單克隆抗體對組織因子（TF）組成的抗體藥物複合物，用於治療晚期實體腫瘤；XL102，一種口服可生物利用的cyclin-dependent kinase 7（CDK7）抑制劑，用於治療晚期或轉移性實體腫瘤；以及XB002，用於治療非霍奇金淋巴瘤。Exelixis, Inc.與Ipsen Pharma SAS、武田製藥株式會社、F. Hoffmann-La Roche Ltd.、Redwood Bioscience, Inc.、R.P. Scherer Technologies, LLC、Catalent Pharma Solutions, Inc.、NBE Therapeutics AG、Aurigene Discovery Technologies Limited、Iconic Therapeutics, Inc.、Invenra, Inc.、StemSynergy Therapeutics, Inc.、Genentech, Inc.、Bristol-Myers Squibb Company和大日本住友製藥株式會社等公司進行研究合作和許可協議。該公司以前被稱為Exelixis Pharmaceuticals, Inc.，並於2000年2月改名為Exelixis, Inc.。Exelixis, Inc.成立於1994年，總部位於加利福尼亞州阿拉米達。

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

公司網址

https://www.exelixis.com